Watchlist

•

	Dow	24,802.62	15.99	0.06%
	S&P 500	2,711.26	4.87	0.18%
	Nasdaq	7,281.10	124.82	1.74%
	GlobalDow	3,102.62	17.19	0.56%
	Gold	1,356.40	6.90	0.51%
	Oil	67.97	1.45	2.18%

S&P 500 Movers(%)

Latest NewsAll Times Eastern

|

RIGL U.S.: Nasdaq

Rigel Pharmaceuticals Inc.

Watchlist CreateRIGLAlert

RIGLUSOpenBack To Top

Last Updated: Apr 18, 2018 9:30 a.m. EDT Real time quote

^$ 4.11

0.00

0.00%

Previous Close
$4.11

Advanced Charting

$
%
Vol

Advanced Charting

24.45% vs Avg.

Volume: 498K 65 Day Avg. - 2M

Open: 4.21

Last: 4.11

4.11 Day Low/High 4.22

Day Range

2.14 52 Week Low/High 4.71

Customize MarketWatch

Have Watchlists? Log in to see them here or sign up to get started.

Create Account … or Log In

	Symbol Company	Price Chg/Chg %

(Go to Your Watchlist)

No Items in Watchlist

There are currently no items in this Watchlist.

Add Tickers

No Saved Watchlists

Create a list of the investments you want to track.

Create Watchlist …or try this starter list

Uh oh

Something went wrong while loading Watchlist.

Go to Watchlist

No Recent Tickers

Visit a quote page and your recently viewed tickers will be displayed here.

Open $4.21
Day Range 4.11 - 4.22
52 Week Range 2.14 - 4.71
Market Cap $605.69M
Shares Outstanding 147.11M
Public Float 143.78M
Beta 1.41
Rev. per Employee $43.53K
P/E Ratio n/a
EPS $-0.61
Yield n/a
Dividend n/a
Ex-Dividend Date n/a
Short Interest 9.61M 03/29/18
% of Float Shorted 6.69%
Average Volume 2.04M

5 Day	5.12%
1 Month	5.66%
3 Month	0.49%
YTD	5.93%
1 Year	35.64%

MarketWatch
Other Dow Jones

No Headlines Available

No Headlines Available

Other News
Press Releases

Rigel Overcomes Its First FDA Approval Barrier, Is There More To Come?

Rigel Overcomes Its First FDA Approval Barrier, Is There More To Come?

Apr. 18, 2018 at 2:43 a.m. ET
on Seeking Alpha

Rigel Pharmaceuticals (RIGL) Wins FDA Approval; BMO Lifts Price Target to $8

It’s a big day for Rigel Pharmaceuticals (NASDAQ:RIGL). The drug maker has just announced that the ...[...]

Apr. 17, 2018 at 5:54 p.m. ET
on SmarterAnalyst

Here's Why Rigel Pharmaceuticals Rose as Much as 10.2% Today

Apr. 17, 2018 at 3:54 p.m. ET
on Motley Fool

Trading in Rigel halted ahead of expected FDA OK for Tavalisse for immune thrombocytopenia; shares up 10%

Trading in Rigel halted ahead of expected FDA OK for Tavalisse for immune thrombocytopenia; shares up 10%

Apr. 17, 2018 at 1:43 p.m. ET
on Seeking Alpha

3 Things In Biotech, April 16: Liver, Liver, And More Liver

3 Things In Biotech, April 16: Liver, Liver, And More Liver

Apr. 17, 2018 at 8:00 a.m. ET
on Seeking Alpha

Biotech Forum: The Week Ahead

Biotech Forum: The Week Ahead

Apr. 16, 2018 at 12:05 p.m. ET
on Seeking Alpha

Rigel Pharmaceuticals' (RIGL) Stock Gains 16%: Here's Why

Shares of Rigel (RIGL) rise given that the FDA's decision on its lead pipeline candidate Tavalisse is nearing.

Apr. 13, 2018 at 11:51 a.m. ET
on Zacks.com

Key events next week - healthcare

Key events next week - healthcare

Apr. 13, 2018 at 9:56 a.m. ET
on Seeking Alpha

Institutional Top Ideas Series: DAFNA Capital Management

Institutional Top Ideas Series: DAFNA Capital Management

Apr. 13, 2018 at 1:03 a.m. ET
on Seeking Alpha

Here's What Caused Rigel Pharmaceuticals' Wild Ride Today

Apr. 12, 2018 at 4:49 p.m. ET
on Motley Fool

4 Biotech Stocks With Leaky Pipelines

4 Biotech Stocks With Leaky Pipelines

Apr. 10, 2018 at 1:50 p.m. ET
on InvestorPlace.com

Rigel Fumbles A Phase 2, Can Stage A Potential Comeback With FDA Approval

Rigel Fumbles A Phase 2, Can Stage A Potential Comeback With FDA Approval

Apr. 9, 2018 at 2:46 a.m. ET
on Seeking Alpha

Why Rigel Is Worth A Look Despite Failed Study In IgAN

Why Rigel Is Worth A Look Despite Failed Study In IgAN

Apr. 6, 2018 at 11:54 a.m. ET
on Seeking Alpha

Rigel Pharmaceuticals (RIGL) Soars: Stock Adds 8.2% in Session

Shares of Rigel Pharmaceuticals (RIGL) rose over 8% yesterday.

Apr. 5, 2018 at 8:41 a.m. ET
on Zacks.com

Rigel Pharmaceuticals To Test The FDA

Rigel Pharmaceuticals To Test The FDA

Apr. 5, 2018 at 3:06 a.m. ET
on Seeking Alpha

Rigel Pharmaceuticals (RIGL) Updates on Fostamatinib Phase 2 In IgAN Top Line Results - Slideshow

Rigel Pharmaceuticals (RIGL) Updates on Fostamatinib Phase 2 In IgAN Top Line Results - Slideshow

Apr. 4, 2018 at 12:12 p.m. ET
on Seeking Alpha

Rigel (RIGL) Sinks on Failure of Mid-Stage Study on Lead Drug

Rigel's (RIGL) stock plunges 13% on the failure of a phase II study on lead drug, fostamatinib, in patients with IgA nephropathy (IgAN).

Apr. 4, 2018 at 10:30 a.m. ET
on Zacks.com

Your Daily Pharma Scoop: Geron Update, Rigel Setback, Bio-Path Results

Your Daily Pharma Scoop: Geron Update, Rigel Setback, Bio-Path Results

Apr. 4, 2018 at 8:00 a.m. ET
on Seeking Alpha

Why Switch, Rigel Pharmaceuticals, and Longfin Slumped Today

Apr. 3, 2018 at 4:36 p.m. ET
on Motley Fool

Here's Why Rigel Pharmaceuticals Inc. Stock Is Slipping Today

Apr. 3, 2018 at 12:14 p.m. ET
on Motley Fool

Rigel Announces FDA Approval of TAVALISSE™ (fostamatinib disodium hexahydrate) for Chronic Immune Thrombocytopenia (ITP) in Adult Patients

Rigel Announces FDA Approval of TAVALISSE™ (fostamatinib disodium hexahydrate) for Chronic Immune Thrombocytopenia (ITP) in Adult Patients

Apr. 17, 2018 at 4:51 p.m. ET
on PR Newswire - PRF

Generic Drugs Stocks' Research Reports Released on Mylan, Momenta Pharma, Rigel Pharma, and SCYNEXIS

Generic Drugs Stocks' Research Reports Released on Mylan, Momenta Pharma, Rigel Pharma, and SCYNEXIS

Apr. 13, 2018 at 6:35 a.m. ET
on PR Newswire - PRF

Rigel Makes Statement Regarding Website Error

Rigel Makes Statement Regarding Website Error

Apr. 12, 2018 at 3:57 p.m. ET
on PR Newswire - PRF

Rigel Announces Topline Data from Proof-of-Concept Phase 2 Study of Fostamatinib in IgA Nephropathy

Rigel Announces Topline Data from Proof-of-Concept Phase 2 Study of Fostamatinib in IgA Nephropathy

Apr. 3, 2018 at 7:00 a.m. ET
on PR Newswire - PRF

Rigel Announces Fourth Quarter and Year End 2017 Financial Results and Provides Company Update

Rigel Announces Fourth Quarter and Year End 2017 Financial Results and Provides Company Update

Mar. 6, 2018 at 4:01 p.m. ET
on PR Newswire - PRF

Rigel Pharmaceuticals, Inc. to Host Earnings Call

Rigel Pharmaceuticals, Inc. to Host Earnings Call

Mar. 6, 2018 at 1:04 p.m. ET
on ACCESSWIRE

Blog Exposure - Rigel Pharma to Exhibit 2 Fostamatinib Presentations at 4th Biennial Summit of Thrombosis & Hemostasis Societies of North America

Blog Exposure - Rigel Pharma to Exhibit 2 Fostamatinib Presentations at 4th Biennial Summit of Thrombosis & Hemostasis Societies of North America

Mar. 5, 2018 at 7:11 a.m. ET
on ACCESSWIRE

Rigel Announces Two Fostamatinib Presentations at the 4th Biennial Summit of the Thrombosis & Hemostasis Societies of North America

Rigel Announces Two Fostamatinib Presentations at the 4th Biennial Summit of the Thrombosis & Hemostasis Societies of North America

Mar. 1, 2018 at 7:30 a.m. ET
on PR Newswire - PRF

Quotidian Technical Highlights on Selected Generic Drugs Stocks -- Rigel Pharma, Medicines Co., Versartis, and Zoetis

Quotidian Technical Highlights on Selected Generic Drugs Stocks -- Rigel Pharma, Medicines Co., Versartis, and Zoetis

Mar. 1, 2018 at 6:25 a.m. ET
on PR Newswire - PRF

Blade Therapeutics Announces Appointment of Ryan Maynard as Chief Financial Officer

Blade Therapeutics Announces Appointment of Ryan Maynard as Chief Financial Officer

Feb. 27, 2018 at 4:05 p.m. ET
on BusinessWire - BZX

Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Year End 2017 Financial Results

Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Year End 2017 Financial Results

Feb. 27, 2018 at 7:30 a.m. ET
on PR Newswire - PRF

New Research: Key Drivers of Growth for SpartanNash, Nustar GP, Hornbeck Offshore Services, TiVo, Eli Lilly, and Rigel Pharmaceuticals -- Factors of Influence, Major Initiatives and Sustained Production

New Research: Key Drivers of Growth for SpartanNash, Nustar GP, Hornbeck Offshore Services, TiVo, Eli Lilly, and Rigel Pharmaceuticals -- Factors of Influence, Major Initiatives and Sustained Production

Feb. 21, 2018 at 7:30 a.m. ET
on GlobeNewswire

Rigel Pharmaceuticals, Inc. Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)

Rigel Pharmaceuticals, Inc. Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)

Feb. 16, 2018 at 5:15 p.m. ET
on PR Newswire - PRF

Rigel Pharmaceuticals, Inc. Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)

Rigel Pharmaceuticals, Inc. Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)

Jan. 26, 2018 at 4:05 p.m. ET
on PR Newswire - PRF

What's Happening With These Generic Drugs Stocks? -- Medicines, Mylan, Neurocrine Biosciences, and Rigel Pharma

What's Happening With These Generic Drugs Stocks? -- Medicines, Mylan, Neurocrine Biosciences, and Rigel Pharma

Jan. 23, 2018 at 6:20 a.m. ET
on PR Newswire - PRF

Rigel Pharmaceuticals, Inc. Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)

Jan. 5, 2018 at 4:05 p.m. ET
on PR Newswire - PRF

Rigel to Provide Business Review and Updated Phase 2 Results for Fostamatinib in AIHA at the 36th Annual J.P. Morgan Healthcare Conference

Jan. 4, 2018 at 7:30 a.m. ET
on PR Newswire - PRF

Rigel Announces Departure of Chief Financial Officer

Dec. 15, 2017 at 7:30 a.m. ET
on PR Newswire - PRF

This Morning's Technical Outlook on Generic Drugs Stocks -- Versartis, Akorn, Rigel Pharma, and Medicines

Dec. 13, 2017 at 6:10 a.m. ET
on PR Newswire - PRF

Rigel Pharmaceuticals, Inc. Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)

Dec. 8, 2017 at 7:05 p.m. ET
on PR Newswire - PRF

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. It focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Its current product development programs include Fostamatinib Oral SYK Inhibitor and R348 Topical Ophthalmic JAK/SYK Inhibitor. The company was founded by Donald G. Payan, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA. (See Full Profile)

Sell
Under
Hold
Over
Buy

Number of Ratings 6 Full Ratings

Benzinga's Top Upgrades, Downgrades For December 15, 2017

Dec. 15, 2017 at 8:57 a.m. ET
on Benzinga.com

Benzinga's Top Upgrades, Downgrades For November 6, 2017

Nov. 6, 2017 at 9:53 a.m. ET
on Benzinga.com

7 Biggest Price Target Changes For Thursday

Sep. 1, 2016 at 9:39 a.m. ET
on Benzinga.com

Name	Chg %	Market Cap
Amgen Inc.	-0.02%	$116.87B
Sangamo Therapeutics Inc.	-1.15%	$1.69B
Infinity Pharmaceuticals Inc.	0.90%	$115.36M
AstraZeneca PLC ADR	-0.03%	$89.28B
ChemoCentryx Inc.	-2.03%	$556.47M

Competitor Data Provided By